载和厚朴酚玉米蛋白纳米递药系统的制备及体外的抗乳腺癌活性

刘丹; 王婧; 王良; 彭瑶

doi:10.16098/j.issn.0529-1356.2020.04.010

PDF(6966 KB)

解剖学报 ›› 2020, Vol. 51 ›› Issue (4) : 536-542. DOI: 10.16098/j.issn.0529-1356.2020.04.010

肿瘤生物学

载和厚朴酚玉米蛋白纳米递药系统的制备及体外的抗乳腺癌活性

刘丹王婧* 王良彭瑶

作者信息 +

Preparation of honokiol-loaded zein nano-drug delivery system and its anti-breast cancer activity in vitro#br#

LIU Dan WANG Jing* WANG Liang PENG Yao

Author information +

文章历史 +

摘要

目的制备低生物毒性载和厚朴酚（HNK）的玉米蛋白（zein）纳米递药系统（Zein-HNK），探讨该系统对乳腺癌细胞系MDA-MB-231的抑制作用。方法抗溶剂法制备Zein-HNK纳米递药系统。考察其粒径、分散度、形貌特征、包封率及体外释放行为。评价该系统对MDA-MB-231细胞增殖、凋亡、迁移和侵袭能力的影响。结果 Zein-HNK纳米递药系统粒径为（83.75±2.95）nm；聚合物分散性指数（PDI）为0.132±0.015；对HNK的包封率为（93.04±1.86）%。体外释放实验24 h释放率： Zein-HNK组为（69.10±1.88）%；阳性对照游离-HNK（Free-HNK）组为（88.90%±2.58）%。细胞毒评价：MDA-MB-231细胞阳性对照Free-HNK组MDA-MB-231细胞IC50为（5.02±0.29）mg/L，MCF-7细胞半抑制浓度（IC50）为（4.72±0.22）mg/L；Zein-HNK组MDA-MB-231细胞IC50为（9.92±1.02）mg/L，MCF-7细胞IC50为（9.35±0.30）mg/L。凋亡率：阴性对照control组（8.73±0.64）%；Zein-HNK组（15.05±0.85）%；阳性对照Free-HNK组（28.54±1.48）%（P<0.05）；迁移指数：control组0.67±0.04；ZeinHNK组0.55±0.03；Free-HNK组0.36±0.03（P<0.05）；侵袭相对数：control组0.66±0.03，Zein-HNK组0.44±0.01和Free-HNK组0.35±0.03（P<0.01）。Western blotting结果显示，Zein-HNK通过降低Bcl-2的表达和增加Bax的表达来诱导细胞凋亡。结论 Zein-HNK纳米递药系统可有效降低HNK的毒副作用，通过抑制乳腺癌细胞增殖，诱导细胞凋亡，同时抑制细胞迁移和侵袭，达到抑制乳腺癌细胞MDA-MB-231活性的目的。

Abstract

Objective To prepare a honokiol (HNK)-loaded zein nano-drug delivery system with low biotoxicity and to investigate its inhibitory effect on MDA-MB-231 breast cancer cells. Methods Zein-HNK nano-drug delivery system was prepared by anti-solvent method . The particle size, dispersion, morphological characteristics, encapsulation efficiency and in vitro release behavior of the system were investigated. The effects of this system on the proliferation, apoptosis, migration and invasion of MDA-MB-231 cells were evaluated. Results The particle size of Zein-HNK was (83.75±2.95) nm and the polymer dispersity index(PDI) of it was 0.132±0.015. The encapsulation efficiency of HNK was (93.04±1.86)%. The in vitro release rate of Free-HNK group was(88.90%±2.58)% and release rate of Zein-HNK group was (69.10±1.88）% at 24 hours. Cytotoxicity evaluation showed the 50% inhibiting concentration(IC₅₀) of MDA-MB-231 cells in the positive control group was (5.02±0.29) mg/L, which of MCF-7 cells was (4.72±0.22) mg/L; and the IC50 of MDA-MB-231 cells in Zein-HNK group was (9.92±1.02) mg/L, which of MCF-7 was (9.35±0.30) mg/L. The apoptotic rates of control group, Zein-HNK group and Free-HNK group were (8.73±0.64)%, (15.05±0.85)% and (28.54±1.48)%, respectively. Migration index was 0.67±0.04 in the control group, 0.55±0.03 in the Zein-HNK group and 0.36±0.03 in the Free-HNK group (P<0.05). The relative number of invasions was 0.66±0.03 in the control group, 0.44±0.01 in the Zein-HNK group and 0.35±0.03 in the Free-HNK group (P<0.01). Western bltting result showed that Zein-HNK induced cell apoptosis by decreasing the expression of Bcl-2 and increasing the expression of Bax. Conclusion Zein-HNK nano-drug delivery system can effectively reduce the toxic and side effects of HNK itself. Zein-HNK nano-drug delivery system can effectively inhibit breast cancer proliferation, induce cell apoptosis, and inhibit cell migration and invasion simultaneously.

导出引用

刘丹王婧王良彭瑶. 载和厚朴酚玉米蛋白纳米递药系统的制备及体外的抗乳腺癌活性[J]. 解剖学报. 2020, 51(4): 536-542 https://doi.org/10.16098/j.issn.0529-1356.2020.04.010

LIU Dan WANG Jing WANG Liang PENG Yao. Preparation of honokiol-loaded zein nano-drug delivery system and its anti-breast cancer activity in vitro#br#[J]. Acta Anatomica Sinica. 2020, 51(4): 536-542 https://doi.org/10.16098/j.issn.0529-1356.2020.04.010

中图分类号： Ｒ944.9

参考文献

［1］ Wang ZQ, Li XR, Wang DS, et al. Concurrently suppressing multidrug resistance and metastasis of breastcancer by co-delivery of paclitaxel and honokiol with pH-sensitive polymeric micelles ［J］. Acta Biomaterialia, 2017, 62(15):144-156.

［2］ Chen ShZh. Research progress of anti-tumor experimental therapy of honokiol and its molecular action targets ［J］. Yao Xue Xue Bao, 2016, 51(2):202-207. (in Chinese)

陈淑珍.和厚朴酚的抗肿瘤实验治疗及其分子作用靶点的研究进展［J］.药学学报, 2016, 51(2):202-207.

［3］ Wolf I, O’ Kelly J, Wakimoto N, et al. Honokiol, a natural biphenyl, inhibits in vitro and in vivo growth of breast cancer through induction of apoptosis and cell cycle arrest ［J］. Int J Oncol, 2007, 30(6):1529-l537.

［4］ Singh T, Prasad R, Katiyar SK. Inhibition of class I histone deacetylases in non-small cell lung cancer by honokiol leads to suppression of cancer cell growth and induction of cell death in vitro and in vivo ［J］. Epigenetics, 2013, 8(1):54-65.

［5］ Guo Y, Liu Z, Hong JA, et al. Nano-structure and properties of maize zein studied by atomic force microscopy ［J］. J Cereal Sci, 2015, 41(3):277-281.

［6］ Wang Y, Padua GW. Nanoscale characterization of zein self-assembly ［J］. Langmuir, 2014, 28(5):2429-2435.

［7］ Wang Y, Padua GW. Formation of zein microphases in ethanol-water ［J］. Langmuir, 2010, 26(15):12897-12901.

［8］ Wang Y, Su CP, Schulmerich M, et al. Characterization of core-shell structures formed by zein ［J］. Food Hydrocolloid, 2015, 30(2):487-494.

［9］ Alqahtani MS, Islam MS, Podaralla S, et al. Food protein-based core-shell nanocarriers for oral drug delivery: effect of shell composition on in-vitro and in-vivo functional performance of zein nanocarriers ［J］. Mol Pharmaceut, 2017, 14(3):757-769.

［10］ Jung IC, Young JJ, Jung HS. Down regulation of Sp1 is involved in honokiol-induced cell cycle arrest and apoptosis in human malignant pleural mesothelioma cells ［J］. Onco Rep, 2013, 29(6):2318-2324.

［11］ Ponnurangam S, Mammen JM, Ramalingam S, et al. Honokiol in combination with radiation targets notch signaling to inhibit colon cancer stem cells ［J］. Mol Cancer Ther, 2012, 11(4): 963-972.

［12］ Nagalingam A, Arbiser JL, Bonner MY, et al. Honokiol activates AMP-activated protein kinase in breast cancer cells via an LKB1-dependent pathway and inhibits breast carcinogenesis ［J］. Breast Cancer Res, 2012, 14(1): R35.

［13］ Ma N, Zhang LN, Wang LK, et al. Changes of capillary lymphatic ultrastructure of mouse S180 transplantation tumors with tumor growth ［J］. Acta Anatomica Sinica, 2015, 46 (4):503-508. (in Chinese)

马楠, 张丽男, 王龙凯, 等. 小鼠S180移植瘤毛细淋巴管超微结构随肿瘤生长的变化［J］. 解剖学报, 2015, 46(4):503-508.

［14］ Su ZG, Chen ML, Xiao YY, et al. ROS-triggered and regenerating anticancer nanosystem: an effective strategy to subdue tumor’s multidrug resistance ［J］. J Control Release, 2014, 196:370-383.

［15］ Guo RQ, Wang QH, Wang XT, et al. Preparation of honokiol liposome and its anti-breast cancer effect in vitro and in vivo ［J］. Drug Evaluation Research, 2017, 40(1):48-53. (in Chinese)

国瑞琪, 王秋红, 王向涛, 等. 和厚朴酚脂质体的制备及其体内外抗乳腺癌作用研究［J］. 药物评价研究, 2017, 40(1): 48-53.

［16］ Jiang H, Zhao PJ, Su D, et al. Paris saponinⅠinduces apoptosis via increasing the Bax/Bcl-2 ratio and Caspase-3 expression in gefitinib-resistant non-small cell lung cancer in vitro and in vivo ［J］. Mol Med Rep, 2014, 9(6):2265-2272.

［17］ Ayinde O, Wang Z, Griffin M.Tissue transglutaminase induces epithelial-mesenchymal-transition and the acquisition of stem cell like characteristics in colorectal cancer cells ［J］. Oncotarget, 2017, 8(12):20025-20041.

［18］ Avtanski DB, Nagalingam A, Bonner M, et al. Honokiol inhibits epithelial-mesenchymal transition in breast cancer cells by targeting signal transducer and activator of transcription 3/Zebl/E-cadherin axis ［J］. Mol Oncol, 2014, 8(3):565-580.